<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01406925</url>
  </required_header>
  <id_info>
    <org_study_id>NRL001-02/2006(SD)</org_study_id>
    <nct_id>NCT01406925</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of a Single Intra-anal Dose of NRL001 in Healthy Volunteers</brief_title>
  <official_title>A Randomised, Placebo-controlled, Double-blind, Cross-over Study in Healthy Men and Women to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Intra-anal Doses of NRL001 for Three Doses Using a Cream Formulation Relative to a Matched Placebo Formulation for Reference</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Norgine</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Norgine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is conducted to explore the safety and tolerability and plasma pharmacokinetics of
      NRL001 after single intra-anal dose of 1mL cream at increasing concentrations.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">June 2007</completion_date>
  <primary_completion_date type="Actual">May 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax of NRL001</measure>
    <time_frame>30 mins, 1, 2, 3, 4, 5, 6, 8 and 12 hours after dosing</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC of NRL001</measure>
    <time_frame>30 mins, 1, 2, 3, 4, 5, 6, 8 and 12 hours after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability of NRL001</measure>
    <time_frame>Up to 12 hours post-dosing</time_frame>
    <description>Spontaneously reported adverse events will be recorded</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Fecal Incontinence</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo control</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose NRL001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5% NRL001 cream</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intermediate dose NRL001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.75% NRL001 cream</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose NRL001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.0% NRL001 cream</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo control</intervention_name>
    <description>Placebo cream</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NRL001 cream</intervention_name>
    <description>Cream for single-dose intra-anal application</description>
    <arm_group_label>Low dose NRL001</arm_group_label>
    <arm_group_label>Intermediate dose NRL001</arm_group_label>
    <arm_group_label>High dose NRL001</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        IN.1) sex: male and female (non-child-bearing potential or using medically adequate
        contraception

        IN.2) race: Caucasian

        IN.3) BW: 50 - 100 kg

        IN.4) BMI: 20 - 28 kg.m-2

        IN.5) age: 21 - 50 years

        IN.6) type: healthy on the basis of specified criteria evaluated at the screening visit

        IN.7) willing and able to provide informed consent

        Exclusion Criteria:

        General

        EX.1) Previous participation in the trial

        EX.2) Participant in any other trial during the last 90 days

        EX.3) Donation of blood during the last 60 days or a history of blood loss exceeding 300 mL
        within the last 3 months

        EX.4) History of any clinically relevant allergy (including hypersensitivity to the trial
        medications)

        EX.5) Presence of acute or chronic infection

        EX.6) Presence or history of any relevant co-morbidity

        EX.7) Resting systolic blood pressure &gt; 140 or &lt; 90 mmHg, diastolic blood pressure &gt; 95 or
        &lt; 50 mmHg

        EX.8) Clinically relevant ECG-abnormalities, prolonged QTc with &gt; 450 msec in males and &gt;
        460 msec in females in particular

        EX.9) Presence of any relevant abnormality in the laboratory safety tests, especially low
        haemoglobin, increased liver enzymes

        EX.10) Positive serology for HBsAg, anti HBc and anti HCV

        EX.11) Positive HIV test

        EX.12) Positive alcohol or urine drug test on recruitment (and upon admission)

        EX.13) History of alcohol and/or drug abuse and/or daily use of &gt; 30 gr alcohol

        EX.14) Smoking more than 15 cigarettes/day or equivalent of other tobacco products

        EX.15) Use of prohibited medication

        EX.16) Suspicion or evidence that the subject is not trustworthy and reliable

        EX.17) Suspicion or evidence that the subject is not able to make a free consent or to
        understand the information in this regard

        General - all females

        EX.18) Positive pregnancy test

        EX.19) Lactating

        EX.20) Not using appropriate contraception in pre-menopausal women (note: under the
        conditions of the present study, women using hormonal contraceptives will be informed that
        this method is not sufficient during the study and that further i.e. mechanical methods
        [condom, diaphragm with spermicidal gel] should be used in addition).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hans Gruss, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>Norgine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital MHAPT Zaritza Johanna</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 29, 2011</study_first_submitted>
  <study_first_submitted_qc>July 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2011</study_first_posted>
  <last_update_submitted>July 29, 2011</last_update_submitted>
  <last_update_submitted_qc>July 29, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 1, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr Hans-Jurgen Gruss</name_title>
    <organization>Norgine</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fecal Incontinence</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

